Investor Presentaiton
Investor Presentation
First six months of 2018
Slide 18
Closing remarks
Solid leadership positions and continued
market opportunities
27% Novo Nordisk value market share in diabetes
care and solid leadership position
~3% insulin market volume growth
46% Novo Nordisk insulin volume market share
with leadership position across all regions
24% GLP-1 volume market growth
47%
40%
Novo Nordisk GLP-1 value market share
with global leadership position
SaxendaⓇ value market share with a global
leadership in the anti obesity market
·
Pipeline and product portfolio
Leading insulin portfolio across long-acting, short-
acting and premix segments
⚫ Best in class GLP-1 offering with VictozaⓇ and
OzempicⓇ and innovative oral GLP-1 in phase 3
• Market leader in weight management with SaxendaⓇ
and multiple clinical obesity development projects
including injectable once weekly semaglutide
• Solid pipeline in Biopharm with somapacitan in
growth hormone deficiency and multiple clinical
development projects in haemophilia
Source: IQVIA MAT May 2018 volume and value (DKK) figures
changing
diabetes
novo nordiskView entire presentation